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eartache of Fc Receptors*
udhir Gupta, MD, PHD, MACP
rvine, California
diopathic dilated cardiomypathy (DCM) is characterized
y the progressive depression of cardiac function and left
entricular dilation in the absence of coronary artery disease.
here is evidence to suggest that humoral immunity plays
n important role in the pathogenesis of DCM. In partic-
lar, the role of autoantibodies in the pathogenesis of DCM
as been emphasized (1). Sera from patients with DCM
how a variety of autoantibodies, including those against
embrane proteins, mitochondrial proteins, heat-shock
roteins, and myocyte structural sarcolemmal proteins. Be-
ause all these antibodies are not present in each patient
ith DCM, it is apparent that all these autoantibodies are
ot pathogenic in DCM. To date, only 2 autoantibodies
ave satisfied the criteria of cause-and-effect relationship for
CM, and both these antibodies display stimulatory activ-
ties. The first comes from a report that program death
eceptor-1 (PD-1) mice develop autoantibodies against
ardiac troponin 1 (cTpn 1) and dilated heart, and second
rom the finding that the injection of autoantibodies against
Tpn-1 from these mice into normal mice induces dilation
nd dysfunction of the heart in recipient mice (2), therefore
stablishing a direct role of anti–cTpn-1 antibody in dila-
ion and dysfunction of heart resembling human DCM.
See page 1684
ecause antibodies to cTpn-1 are present in approximately
5% of patients with DCM (3), it suggests that additional
utoantibodies and/or mechanisms may be responsible for
CM. Second, autoantibody, which satisfies the cause-and-
ffect relationship, is an autoantibody against 1-adrenergic
eceptor. Mice immunized with a synthetic peptide corre-
ponding to the sequences of the second extracellular loop of
1-adrenergic receptor developed both stimulatory 1-
drenergic receptor antibody and development of disease
esembling DCM. Isogenic transfer of stimulatory anti–1-
drenergic receptor antibodies from cardiomypathic mice
nto healthy inbred mice reproduced the disease (4). Be-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.e
From the Division of Basic and Clinical Immunology, University of California,
rvine, California.ause 1-adrenergic receptors are ubiquitously expressed,
hy other tissues/organs are not affected remains an
nigma. The role of autoantibodies in the pathogenesis of
CM is supported further by effectiveness of removal of
utoantibodies by immunoadsorption on both cardiac func-
ions and clinical improvement in patients with DCM (5,6).
How these autoantibodies induce changes characteristics
f DCM remains unclear; antibody-mediated complement-
ependent cytotoxicity and apoptosis of cardiomyocytes
ave been suggested (7). Because 1-adrenergic receptor
ntibody increases voltage-dependent calcium flux, an
ncrease in free intracellular calcium may trigger apopto-
is in cardiomyocytes via the endoplasmic reticulum-
itochondrial pathway (8,9). Because anion nucleotide
ransporter (ANT) is a component of mitochondrial trans-
ort pore, which plays a role in apoptosis, and ANT
utoantibodies are present in patients with DCM, it would
e of interest to determine whether anti-ANT antibodies
re present in subgroup of patients with DCM who are
ositive for 1-adrenergic receptor antibodies. Antibody-
nduced apoptosis of cardiomyocytes may be one of the
echanisms for pathogenesis of DCM because there is very
ittle inflammatory response in DCM, a characteristic of
poptosis.
In this issue of the Journal, Staudt et al. (10) have
resented evidence to suggest that binding of autoantibody
o both cardiac antigen and to the Fc receptor IIa (CD32a)
lays an important role in the pathogenesis of DCM. In the
rst set of experiments, they demonstrated an involvement
f F(ab=)2 of immunoglobulin (Ig)G in inducing negative
sotropic effect. They showed that intact IgG from sera of
atients with DCM, and not from healthy controls, induced
negative inotropic effect in rat cardiomycytes, whereas
(ab=)2 fragments of patient IgG did not produce a negative
notropic effect, suggesting that F(ab=)2 fragments alone
ere not sufficient to induce negative inotropic effects.
owever, an involvement of the F(ab=)2 fragment from
atient IgG was substantiated by experiments, which dem-
nstrated that preincubation of cardiac myocytes with pa-
ient IgG F(ab=)2 and not from control F(ab=)2 blocked the
egative inotropic effect of patient’s intact IgG.
In the second set of experiments, they demonstrated a
ole Fc of IgG in inducing negative inotropic effect. They
emonstrated that preincubation of cardiomycytes with Fc
ragments of normal IgG blocked the negative inotropic
ffect of intact IgG of DCM, suggesting that the Fc portion
f IgG antibodies is involved. To further demonstrate that
oth Fab and Fc portion of IgG were involved, authors
reconstituted” Fc by sequential incubation of cardiomyo-
ytes with F(ab=)2 of DCM IgG, followed by intact goat
nti-human F(ab=)2 IgG, and demonstrated that “reconsti-
uted” Fc regain the negative inotropic effect of F(ab=)2, in
ontrast, preincubation with control F(ab=)2 IgG and then
econstitution with goat antihuman F(ab=)2 IgG had no
ffect. These experiments do not exclude a possibility that
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(ab=)2. F(ab=)2 fragments of goat antihuman F(ab=)2 IgG
devoid of Fc) and CD32a knock out by small interference
NA, would establish whether both binding to cardiac
ntigen (via Fab) and CD32a are required for autoantibody-
nduced negative inotropic effects.
In the last set of experiments, authors examined the
xpression of different Fc receptors and observed the
resence on CD32a and none other receptors. Therefore,
hey concluded that CD32a plays an important role in
utoantibodies-mediated pathogenesis of DCM.
A role of Fc receptors in autoimmunity has been sup-
orted by knock out and transgenic experiments (11). Eight
c receptors have been defined in humans, including 3
igh-affinity and 5 low-affinity receptors (12). All these Fc
eceptors, with the exception of Fc receptor IIb (CD32b),
ave intracytoplasmic immunotyrosine activation motif
stimulatory receptors); CD32b containing immunotyrosine
nhibitory motif (inhibitory receptor). Although monomeric
gG may bind to CD32a, it does not induce any signal, and
nly immune complexes when interacting with CD32a
nduce activating signals. However, in the study by Staudt et
l. (10), no immune complexes were used to induce signals
ia CD32a. They also have reported that in DCM autoan-
ibodies of IgG3 subclass induces negative inotropic effects
13). Because the IgG3 subclass has a greater tendency to
ggregate (simulate immune complexes), a possibility of
ggregation of intact IgG and Fc fragments from DCM
hould be ruled out. It is intriguing how CD32a with an
TAM motif provides a negative signal. Both anti-cTpn
nd anti–1-adrenergic antibodies induce positive signals.
taudt et al. (10) have demonstrated the presence of CD32a
n cardiomyocytes from DCM and the lack of CD32b,
hich mediates inhibitory signal. However, there are certain
imitations to their studies of CD32. First, CD32 antibodies
sed are raised against extracellular domain of CD32, which
as a high degree of homology between CD32 subtypes
nd, therefore, does not distinguish between CD32a and
D32b. Second, because no studies were performed with
ardiomyocytes from a healthy heart, it is unclear whether
he density of CD32b is reduced in cardiomyocytes from
CM and, thus, not detected by a relatively insensitive
echnique of immunofluorescence microscopy. Therefore,
tudies should be performed with cardiomyocytes from a
ealthy heart and from DCM with antibodies that distin-
uish CD32a from CD32b. In addition, the use of more
ensitive techniques, including flow cytometry and real time
CR, should be used.
Several studies have reported beneficial effects of high-
ose intravenous immunoglobulin (IVIG) on cardiac func-
ions in patients with dilated cardiomyopathy (14–16).
owever, underlying mechanisms remain unclear. Larsson
t al. (15) reported that the beneficial effect of IVIG on
ardiac functions in DCM is not caused by neutralization of
nti-1 adrenergic receptor antibody (anti-idiotypic effect).
ullestad et al. (16) observed an induction of anti-nflammatory mediators interleukin-10, interleukin-1 re-
eptor antagonist, and soluble tumor necrosis factor recep-
ors in the IVIG-treated group and none in the placebo
roup in patients with DCM. Because one of the major
echanisms of beneficial effects of IVIG in autoimmune
iseases is via stimulation of CD32b (12), it is crucial that
he expression of CD32b in cardiomyocytes be investigated
n detail.
In summary, certain autoantibodies appear to play a
athogenic role in patients with DCM. Several mechanisms
f autoantibody-mediated dysfunction/damage to cardiac
yocytes, including complement-mediated cytotoxicity and
poptosis, have been reported (7). Staudt and et al. (10) have
rovided data in support of a role of Fc receptors in DCM.
lthough there are limitations with their investigation, the
tudy of the role of Fc receptors by Staudt et al. (10) should
ncourage investigators to explore this novel pathway to
nderstand the pathogenesis of DCM and other autoim-
une cardiac diseases. It is important that the patients with
CM be subclassified according to the presence of patho-
enic antibodies and that these pathogenic antibodies
hould be used in the study of the mechanisms of DCM and
s a target for removal by immunoadsorption using specific
olumns. It is critical that the entire protein, rather than a
eptide, be used in immunoadsorption columns because the
pitopes recognized by autoantibodies may be different in
ifferent patients. Furthermore, multicenter double-blind
ontrol-placebo trials of high-dose IVIG should be initiated
nd perhaps compared with that of immunoadsorption.
ecause the disease can be transferred by lymphocytes (17),
nti-CD20 antibody treatment (to remove autoreactive B
ells), similar to other autoimmune diseases, may be effec-
ive in treating DCM and other autoimmune myocarditis. It
s likely that immunoadsorption/IVIG/anti-CD20 mono-
lonal antibodies therapy would replace cardiac transplan-
ation, at least in a subset of patients with DCM, where
utoantibodies are demonstrated to be pathogenic.
eprint requests and correspondence: Dr. Sudhir Gupta, Med-
cal Sciences I, C-240, University of California, Irvine, California
2697. E-mail: sgupta@uci.edu.
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